FDA Introduces ‘PreCheck’ Plan to Strengthen US Drug Facilities - Bloomberg Law News
FDA introduces 'PreCheck' plan to enhance oversight of drug facilities, focusing on compliance with cGMP standards and drug approval processes.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Implementation of the 'PreCheck' plan to strengthen compliance with current Good Manufacturing Practices (cGMP) and improve drug approval processes.
Who it affects
All pharmaceutical manufacturers including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities.
What you must do
Review and enhance compliance protocols to align with the new FDA 'PreCheck' requirements.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA approved cannabis: Why Schedule 3 means operators must prepare for pharmaceutical-grade MMJ now - MJBizDaily
- Update: State Disclosure and Transparency Laws for Pharmaceutical and Medical Device Manufacturers - McGuireWoods
- White House defends FDA's approval of second generic abortion pill amid GOP criticism - thenationaldesk.com
- FDA Launches Aggressive Crackdown on Direct-to-Consumer Drug Advertising It Considers Misleading - jdsupra.com
- AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight - endpoints.news